Neuroimmune Disease
Conditions
Interventions
None listed
Sponsors
The Japanese Society for Neuroimmunology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: As follows: Chronic inflammatory demyelinating polyneuropathy (CIDP) 1) Patients who diagnosed the EFNS/PNS diagnostic criteria 2010 definite, probable, possible 2) Patients who have given written consent to participate in the study Anti myelin associated glycoprotein (MAG) antibody associated neuropathy 1) Patients with demyelinating polyneuropathy and anti-MAG or anti-SGPG antibody positive. 2) Patients who have given written consent to participate in the study Multifocal motor neuropathy (MMN) 1) Patients who meet the EFNS/PNS diagnostic criteria 2010 definite, probable, possible 2) Patients who give written consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients deemed inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The course of clinical endpoints mainly used for each neuroimmune disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. EQ-5D-5L 2. Treatment response 3. Frequency of adverse events | — |
Countries
Japan
Contacts
Public ContactShigeki Omori
General Incorporated Association kizuna Secretariat
Outcome results
None listed